The CARE™ Rheumatology Perspectives report provides a Canadian perspective on relevant clinical trials and news in inflammatory arthritis. Content Foci: Multi disease Rheumatoid Arthritis Psoriatic Arthritis Axial Spondyloarthritis Summary and…

Introduction   CARE™ Hematology Faculty lead, Dr. Peter Anglin, connects virtually with Dr. Versha Banerji to discuss Considerations for treatment rrCLL. const evplayerplyr638232f509f77 = new Plyr(document.getElementById('plyr638232f509f77')); evplayerplyr638232f509f77.ratio = '16:9'; evplayerplyr638232f509f77.iconUrl...

The 12th annual Canadian Hematology Conference meeting was streamed on Sept. 30th - Oct. 1st 2022. As a follow-up to the meeting, all video components and slide decks are featured in the CHC 2022 virtual...

Introduction   Dr. Alison Moskowitz, Memorial Sloan Kettering Cancer Centre, NY, spoke with CARE™ Hematology Faculty lead, Dr. Peter Anglin, Stronach Regional Cancer Centre, on approaches in frontline advanced Hodgkin...

Introduction Dr. Alison Moskowitz (Memorial Sloan Kettering Cancer Centre, NY) connects virtually with CARE™ Hematology Faculty lead, Dr. Peter Anglin (Stronach Regional Cancer Centre, ON), to discuss treatment of advanced...

Introduction   CARE™ Hematology Faculty lead, Dr. Peter Anglin (Stronach Regional Cancer Centre, ON), connected virtually with international expert Dr. Stephan Stilgenbauer to discuss Considerations for treatment of two separate...

Welcome to Part 2 of the 2022 Forum on Complement Case Discussion Series. PNH is an ultra-rare, and under-recognized complement-mediated disease. Despite its rarity this disease warrants our attention because…

Welcome to the Part 2 of the 2022 HPP Case Discussion. In October 2021- January 2022, insights on current perceptions and practice patterns were collected from specialists across Canada via a…

Welcome to the Part 1 of the 2022 Forum on Complement Case Discussion.

Introduction   The armamentarium of therapies available for our CLL patients has rapidly grown in recent years. As novel agents have become integrated into routine practice, navigating optimal use and...